SCHEMBL512243

SCHEMBL512243

Cc1ccc([N+](=O)[O-])c(N2CCC(=Cc3nc4ccccc4o3)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 7/20 0.46
CYP3A4 P08684 1/20 0.42
MAPT P10636 7/20 0.38
ALDH1A1 P00352 4/20 0.38
MAPK1 P28482 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
POLB P06746 2/20 0.38
LMNA P02545 4/20 0.36
ADAMTS5 Q9UNA0 1/20 0.36
KMT2A Q03164 2/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
MMP8 P22894 1/20 0.34
MMP13 P45452 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL512619 0.82 GRM5 (0.46) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL514979 0.81 GRM5 (0.48) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL512661 0.81 GRM5 (0.47) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL512667 0.80 GRM5 (0.48) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL512658 0.79 GRM5 (0.48) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL513331 0.79 GRM5 (0.47) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL513812 0.78 GRM5 (0.45) GRM5CYP3A4MAPTPOLBKMT2A
SCHEMBL513105 0.78 GRM5 (0.46) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL513719 0.78 GRM5 (0.48) GRM5CYP3A4MAPTALDH1A1MAPK1
SCHEMBL512730 0.77 GRM5 (0.45) GRM5CYP3A4MAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US claimed
EP-2477981-A1 HETEROCYCLIC MGLU5 ANTAGONISTS Recordati Ireland Limited (IE) 2012-07-25 EP disclosed
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS OPRM1, GRM5, OPRD1 GRM5 2/4885CYP3A4 1085/4885MAPT 2573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.